TelyRx Holdings (TELY) Global Technology Virtual Investor Conference summary
Event summary combining transcript, slides, and related documents.
Global Technology Virtual Investor Conference summary
14 Jul, 2026Market opportunity and business model
Addresses the inefficiencies in traditional pharmacy by offering over 450 everyday medications delivered quickly, without appointments, insurance, or lines.
Operates in the $98 billion cash-pay prescription market, growing at 40% annually, and avoids the regulatory hurdles faced by insurance-based competitors.
100% cash-pay model enables full control over the value chain, from physician access to fulfillment, with no exposure to government reimbursement regulations.
Focuses on high-use, low-risk medications, ensuring broad reach and diversification across eight clinical categories.
Built for scalability with two strategically located pharmacies covering 97% of the U.S. population.
Financial performance and growth
Achieved $43 million in revenue last year, with over 50% compounded quarterly growth and 70% of revenue from repeat customers.
Q1 revenue reached $19.4 million, up 180% year-over-year and 35% quarter-over-quarter, with gross margins expanding to 55%.
Customer acquisition cost is $113, with a three-month payback period and average customer lifetime revenue of $524, which continues to grow.
Marketing spend yields a 3x return, and the company has transitioned to a fully in-house marketing team to drive further efficiency.
Gross profit margin improved from 37% to 54% in year two, with ongoing focus on margin expansion and disciplined growth.
Customer dynamics and retention
Nearly 50% of new customers become repeat buyers, with 20% making a second purchase within seven days and 60% within 30 days.
Average order value increases by 15% on follow-on transactions, and recurring customers drive the majority of revenue.
Investments in customer experience and technology aim to further increase retention and lifetime value.
Key KPIs tracked include lifetime revenue, customer acquisition cost, new vs. recurring customer mix, and prescription type distribution.
Plans to enhance customer engagement and platform features are underway, with more updates expected in upcoming quarters.
Latest events from TelyRx Holdings
- Rapidly scaling digital pharmacy targets the $98B cash-pay market with proven, high-margin growth.TELY
Small Cap Growth Virtual Investor Conference5 Jun 2026 - Rapidly scaling, vertically integrated pharmacy delivers 450+ medications with strong revenue growth.TELY
Investor presentation4 Jun 2026 - Revenue up 180% to $19.4M, prescriptions up 188%, net loss at $4.7M, cash at $27M.TELY
Q1 202613 May 2026 - 2025 revenue soared 350% year-over-year, driven by rapid growth in prescriptions filled.TELY
Q4 202513 May 2026 - Digital pharmacy achieves rapid growth and profitability with a scalable, cash-pay model.TELY
Investor presentation13 May 2026